The RGD-containing peptide fragment of osteopontin protects tyrosine hydroxylase positive cells against toxic insult in primary ventral mesencephalic cultures and in the rat substantia nigra

Journal of Neurochemistry

Volumn 114, Issue 6, 2010, Pages 1792-1804

  Iczkiewicz, Joanna ^a   Broom, Lauren ^a   Cooper, Jonathan D ^a   Wong, Andrew Ming Sham ^a   Rose, Sarah ^a   Jenner, Peter ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

gliosis; neuroprotection; osteopontin; Parkinson's disease; RGD containing peptide fragment; substantia nigra; tyrosine hydroxylase

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; INTEGRIN; LIPOPOLYSACCHARIDE; OSTEOPONTIN; OXIDOPAMINE; PEPTIDE FRAGMENT; PROTEIN ANTIBODY; TYROSINE 3 MONOOXYGENASE; 1 METHYL 4 PHENYLPYRIDINIUM; ANTIBODY; ARGINYL-GLYCYL-ASPARTIC ACID; OLIGOPEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL LOSS; CELL SURVIVAL; CONTROLLED STUDY; GLIOSIS; IMMUNOHISTOCHEMISTRY; MALE; MESENCEPHALON; NERVE CELL; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; STEREOMETRY; SUBSTANTIA NIGRA; TISSUE CULTURE; ANIMAL; CELL CULTURE; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; ENZYMOLOGY; GLIA; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; WISTAR RAT;

RATTUS;

1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; ANTIBODIES; CELL COUNT; CELL SURVIVAL; CELLS, CULTURED; LIPOPOLYSACCHARIDES; MALE; MESENCEPHALON; NEUROGLIA; NEURONS; OLIGOPEPTIDES; OSTEOPONTIN; OXIDOPAMINE; RATS; RATS, WISTAR; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 77956313129     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2010.06896.x     Document Type: Article

References (50)

1. Attur M. G., Dave M. N., Clancy R. M., Patel I. R., Abramson S. B. Amin A. R. (2000) Functional genomic analysis in arthritis-affected cartilage: yin-yang regulation of inflammatory mediators by alpha 5 beta 1 and alpha V beta 3 integrins. J. Immunol. 164, 2684 2691.
2. Bautista D. S., Saad Z., Chambers A. F., Tonkin K. S., O'Malley F. P., Singhal H., Tokmakejian S., Bramwell V. Harris J. F. (1996) Quantification of osteopontin in human plasma with an ELISA: basal levels in pre- and postmenopausal women. Clin. Biochem. 29, 231 239.
3. Brown L. F., Berse B., Van de Water L., Papadopoulos-Sergiou A., Perruzzi C. A., Manseau E. J., Dvorak H. F. Senger D. R. (1992) Expression and distribution of osteopontin in human tissues: widespread association with luminal epithelial surfaces. Mol. Biol. Cell 3, 1169 1180.
4. Burdo T. H., Ellis R. J. Fox H. S. (2008) Osteopontin is increased in HIV-associated dementia. J. Infect. Dis. 198, 715 722.
5. Chowdhury S. A., Lin J. Sadiq S. A. (2008) Specificity and correlation with disease activity of cerebrospinal fluid osteopontin levels in patients with multiple sclerosis. Arch. Neurol. 65, 232 235.
6. Denda S., Reichardt L. F. Muller U. (1998) Identification of osteopontin as a novel ligand for the integrin alpha8 beta1 and potential roles for this integrin-ligand interaction in kidney morphogenesis. Mol. Biol. Cell 9, 1425 1435.
7. Denhardt D. T., Giachelli C. M. Rittling S. R. (2001a) Role of osteopontin in cellular signaling and toxicant injury. Annu. Rev. Pharmacol. Toxicol. 41, 723 749.
8. Denhardt D. T., Noda M., O'Regan A. W., Pavlin D. Berman J. S. (2001b) Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J. Clin. Invest. 107, 1055 1061.
9. Doyle K. P., Yang T., Lessov N. S., Ciesielski T. M., Stevens S. L., Simon R. P., King J. S. Stenzel-Poore M. P. (2008) Nasal administration of osteopontin peptide mimetics confers neuroprotection in stroke. J. Cereb. Blood Flow Metab. 28, 1235 1248.
10. Ellison J. A., Velier J. J., Spera P., Jonak Z. L., Wang X., Barone F. C. Feuerstein G. Z. (1998) Osteopontin and its integrin receptor alpha(v)beta3 are upregulated during formation of the glial scar after focal stroke. Stroke 29, 1698 1706. discussion 1707.
11. Gall C. M., Pinkstaff J. K., Lauterborn J. C., Xie Y. Lynch G. (2003) Integrins regulate neuronal neurotrophin gene expression through effects on voltage-sensitive calcium channels. Neuroscience 118, 925 940.
12. Gary D. S. Mattson M. P. (2001) Integrin signaling via the PI3-kinase-Akt pathway increases neuronal resistance to glutamate-induced apoptosis. J. Neurochem. 76, 1485 1496.
13. Gary D. S., Milhavet O., Camandola S. Mattson M. P. (2003) Essential role for integrin linked kinase in Akt-mediated integrin survival signaling in hippocampal neurons. J. Neurochem. 84, 878 890.
14. Hu D. D., Lin E. C., Kovach N. L., Hoyer J. R. Smith J. W. (1995) A biochemical characterization of the binding of osteopontin to integrins alpha v beta 1 and alpha v beta 5. J. Biol. Chem. 270, 26232 26238.
15. Hwang S. M., Wilson P. D., Laskin J. D. Denhardt D. T. (1994) Age and development-related changes in osteopontin and nitric oxide synthase mRNA levels in human kidney proximal tubule epithelial cells: contrasting responses to hypoxia and reoxygenation. J. Cell. Physiol. 160, 61 68.
16. Iczkiewicz J., Rose S. Jenner P. (2004) Osteopontin (Eta-1) is present in the rat basal ganglia. Brain Res. Mol. Brain Res. 132, 64 72.
17. Iczkiewicz J., Rose S. Jenner P. (2005) Increased osteopontin expression following intranigral lipopolysaccharide injection in the rat. Eur. J. Neurosci. 21, 1911 1920.
18. Iczkiewicz J., Jackson M. J., Smith L. A., Rose S. Jenner P. (2006) Osteopontin expression in substantia nigra in MPTP-treated primates and in Parkinson's disease. Brain Res. 1118, 239 250.
19. Iczkiewicz J., Rose S. Jenner P. (2007) Osteopontin expression in activated glial cells following mechanical- or toxin-induced nigral dopaminergic cell loss. Exp. Neurol. 207, 95 106.
20. Kang W. S., Choi J. S., Shin Y. J., Kim H. Y., Cha J. H., Lee J. Y., Chun M. H. Lee M. Y. (2008) Differential regulation of osteopontin receptors, CD44 and the alpha(v) and beta(3) integrin subunits, in the rat hippocampus following transient forebrain ischemia. Brain Res. 1228, 208 216.
21. Khan S. A., Lopez-Chua C. A., Zhang J., Fisher L. W., Sorensen E. S. Denhardt D. T. (2002) Soluble osteopontin inhibits apoptosis of adherent endothelial cells deprived of growth factors. J. Cell. Biochem. 85, 728 736.
22. Kim J. M., Lee K. H., Jeon Y. J., Oh J. H., Jeong S. Y., Song I. S., Lee D. S. Kim N. S. (2006) Identification of genes related to Parkinson's disease using expressed sequence tags. DNA Res. 13, 275 286.
23. King V. R., McBride A. Priestley J. V. (2001) Immunohistochemical expression of the alpha5 integrin subunit in the normal adult rat central nervous system. J. Neurocytol. 30, 243 252.
24. Maetzler W., Berg D., Schalamberidze N., Melms A., Schott K., Mueller J. C., Liaw L., Gasser T. Nitsch C. (2007) Osteopontin is elevated in Parkinson's disease and its absence leads to reduced neurodegeneration in the MPTP model. Neurobiol. Dis. 25, 473 482.
25. Maetzler W., Michelis J., Tomiuk J., Melms A., Becker C., Gasser T., Schulte C. Berg D. (2009) A single-nucleotide polymorphism of the osteopontin gene may contribute to a susceptibility to Lewy body disease. J. Neural. Transm. 116, 599 605.
26. McNaught K. S. Jenner P. (1999) Altered glial function causes neuronal death and increases neuronal susceptibility to 1-methyl-4-phenylpyridinium- and 6-hydroxydopamine-induced toxicity in astrocytic/ventral mesencephalic co-cultures. J. Neurochem. 73, 2469 2476.
27. Meller R., Stevens S. L., Minami M. et al. (2005) Neuroprotection by osteopontin in stroke. J. Cereb. Blood Flow Metab. 25, 217 225.
28. Noiri E., Dickman K., Miller F. et al. (1999) Reduced tolerance to acute renal ischemia in mice with a targeted disruption of the osteopontin gene. Kidney Int. 56, 74 82.
29. O'Brien E. R., Garvin M. R., Stewart D. K., Hinohara T., Simpson J. B., Schwartz S. M. Giachelli C. M. (1994) Osteopontin is synthesized by macrophage, smooth muscle, and endothelial cells in primary and restenotic human coronary atherosclerotic plaques. Arterioscler. Thromb. 14, 1648 1656.
30. Okada H., Moriwaki K., Kalluri R., Takenaka T., Imai H., Ban S., Takahama M. Suzuki H. (2000) Osteopontin expressed by renal tubular epithelium mediates interstitial monocyte infiltration in rats. Am. J. Physiol. Renal Physiol. 278, F110 F121.
31. Olanow C. W. (2009) Can we achieve neuroprotection with currently available anti-parkinsonian interventions? Neurology 72, S59 S64.
32. Olanow C. W., Schapira A. H. Agid Y. (2003) Neuroprotection for Parkinson's disease: prospects and promises. Ann. Neurol. 53 (Suppl 3 S1 S2.
33. Olanow C. W., Kieburtz K. Schapira A. H. (2008) Why have we failed to achieve neuroprotection in Parkinson's disease? Ann. Neurol. 64 (Suppl 2 S101 S110.
34. O'Regan A. W., Chupp G. L., Lowry J. A., Goetschkes M., Mulligan N. Berman J. S. (1999) Osteopontin is associated with T cells in sarcoid granulomas and has T cell adhesive and cytokine-like properties in vitro. J. Immunol. 162, 1024 1031.
35. Paxinos G. Watson C. (1986) The Rat Brain in Stereotaxic Co-ordinates. Academic Press Ltd, London.
36. Pinkstaff J. K., Lynch G. Gall C. M. (1998) Localization and seizure-regulation of integrin beta 1 mRNA in adult rat brain. Brain Res. Mol. Brain Res. 55, 265 276.
37. Pinkstaff J. K., Detterich J., Lynch G. Gall C. (1999) Integrin subunit gene expression is regionally differentiated in adult brain. J. Neurosci. 19, 1541 1556.
38. Rollo E. E. Denhardt D. T. (1996) Differential effects of osteopontin on the cytotoxic activity of macrophages from young and old mice. Immunology 88, 642 647.
39. Rollo E. E., Laskin D. L. Denhardt D. T. (1996) Osteopontin inhibits nitric oxide production and cytotoxicity by activated RAW264.7 macrophages. J. Leukoc. Biol. 60, 397 404.
40. Scatena M., Almeida M., Chaisson M. L., Fausto N., Nicosia R. F. Giachelli C. M. (1998) NF-kappaB mediates alphavbeta3 integrin-induced endothelial cell survival. J. Cell Biol. 141, 1083 1093.
41. Schapira A. H. Olanow C. W. (2004) Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA 291, 358 364.
42. Schroeter M., Zickler P., Denhardt D. T., Hartung H. P. Jander S. (2006) Increased thalamic neurodegeneration following ischaemic cortical stroke in osteopontin-deficient mice. Brain 129, 1426 1437.
43. Scott J. A., Weir M. L., Wilson S. M., Xuan J. W., Chambers A. F. McCormack D. G. (1998) Osteopontin inhibits inducible nitric oxide synthase activity in rat vascular tissue. Am. J. Physiol. 275, H2258 H2265.
44. Shin S. L., Cha J. H., Chun M. H., Chung J. W. Lee M. Y. (1999) Expression of osteopontin mRNA in the adult rat brain. Neurosci. Lett. 273, 73 76.
45. Stocchi F. Olanow C. W. (2003) Neuroprotection in Parkinson's disease: clinical trials. Ann. Neurol. 53 (Suppl 3 S87 S97. discussion S97-99.
46. Weber G. F., Adler G. Ashkar S. (1999) Osteopontin in oxidative stress responses, in Inflammatory Cells and Mediators in CNS Disease (FRuffolo R. R. J., Feuerstein G. Z., Hunter A. J., Poste G. Metcalf B. W., eds), pp. 97 112. Harwood Academic Publishers, Amsterdam.
47. West M. J., Slomianka L. Gundersen H. J. (1991) Unbiased stereological estimation of the total number of neurons in thesubdivisions of the rat hippocampus using the optical fractionator. Anat. Rec. 231, 482 497.
48. Wirths O., Breyhan H., Marcello A., Cotel M. C., Bruck W. Bayer T. A. (2008) Inflammatory changes are tightly associated with neurodegeneration in the brain and spinal cord of the APP/PS1KI mouse model of Alzheimer's disease. Neurobiol. Aging 31, 747 757.
49. Xie Y., Sakatsume M., Nishi S., Narita I., Arakawa M. Gejyo F. (2001) Expression, roles, receptors, and regulation of osteopontin in the kidney. Kidney Int. 60, 1645 1657.
50. Yan Y. P., Lang B. T., Vemuganti R. Dempsey R. J. (2009) Osteopontin is a mediator of the lateral migration of neuroblasts from the subventricular zone after focal cerebral ischemia. Neurochem. Int. 55, 826 832.